| abstract |
Novel bispecific human monoclonal antibodies (bs-mAbs) are directed against two neutralizing epitopes of human immunodeficiency virus (HIV). Such bs-mAbs, specific for two V3 loop epitopes, or specific for a V3 loop epitope and a CD4-binding domain epitope, are effective in neutralizing HIV and can be used for prophylactic or therapeutic administration to subjects with HIV infection and AIDS. Also provided are pharmaceutical compositions comprising one or more bs-mAbs, cell lines producing such bs-mAbs, methods for producing such cell lines and methods for producing the bs-mAbs. |